Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03858205 · ClinicalTrials.gov registry record · NA

Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma

A NA study of Plasma Cell Myeloma and Metastatic Malignant Neoplasm in the Bone, sponsored by University of Southern California.

Recruiting
Registry status
NA
Development phase
100
Enrollment target
9
Study locations

NCT03858205 is a NA study of Plasma Cell Myeloma and Metastatic Malignant Neoplasm in the Bone that is actively recruiting participants, run by University of Southern California. The registered enrollment target is 100 participants, below the 205-participant average among 32 other Plasma Cell Myeloma trials with a reported enrollment target (51% lower). The trial reports 9 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03858205, a NA study of Plasma Cell Myeloma and Metastatic Malignant Neoplasm in the Bone, is actively recruiting participants, sponsored by University of Southern California.

RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
9
Study locations

Study Summary

This phase II trial studies how well low-dose radiotherapy works in treating bone pain in patients with multiple myeloma that has spread to the bone. Radiation therapy uses high energy x-rays, gamma rays, neutrons, protons, or other sources to kill tumor cells and shrink tumors. Low-dose radiotherapy may be more convenient for patients and their families, may not interfere as much with the timing of chemotherapy, and may have less chance for short term or long-term side effects from the radiation.

Interventions

  • OTHER Quality-of-Life Assessment
  • OTHER Questionnaire Administration
  • RADIATION Radiation Therapy

Study Locations (9)

California

  • City of Hope - Duarte
  • Los Angeles General Medical Center - Los Angeles
  • USC / Norris Comprehensive Cancer Center - Los Angeles
  • Cedars Sinai Medical Center - Los Angeles

Georgia

  • Emory University Hospital/Winship Cancer Institute - Atlanta

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Minnesota

  • University of Minnesota - Masonic Cancer Center - Minneapolis

New York

  • Icahn School of Medicine at Mount Sinai - New York

Pennsylvania

  • University of Pennsylvania/Abramson Cancer Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2019-03-11
Est. Completion 2027-03-11
Phase NA

Sponsor

University of Southern California

617 total trials

What the Registry Record Tells You About NCT03858205

The ClinicalTrials.gov registry entry for NCT03858205 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 32 other Plasma Cell Myeloma trials with a reported enrollment target (51% lower). The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Plasma Cell Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.

NCT03858205 reports 9 study locations spanning 6 distinct geographic areas - top geographies include California, Georgia, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03858205 about?

NCT03858205 is a clinical study titled "Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma". This phase II trial studies how well low-dose radiotherapy works in treating bone pain in patients with multiple myeloma that has spread to the bone. Radiation therapy uses high energy x-rays, gamma rays, neutrons, protons, or other sources to kill tumor cells and shrink tumors. Low-dose radiotherap...

What is the current status of trial NCT03858205?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2019-03-11. Estimated completion is 2027-03-11.

What conditions does trial NCT03858205 study?

This clinical trial studies the following conditions: Plasma Cell Myeloma, Metastatic Malignant Neoplasm in the Bone, Bone Pain.

What interventions are being tested in trial NCT03858205?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Radiation Therapy (RADIATION).

Who is sponsoring clinical trial NCT03858205?

This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03858205 being conducted?

This trial has 9 study locations across California, Georgia, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Plasma Cell Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.